• 1. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 2. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

Recent Advances in the Study of N-(3-aminophenyl)hexanamide (CAS: 231954-22-6)

N-(3-aminophenyl)hexanamide (CAS: 231954-22-6) has recently emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique structural properties, has been the subject of multiple studies aimed at exploring its potential therapeutic applications. The compound's molecular structure, featuring a hexanamide group linked to a 3-aminophenyl moiety, suggests potential interactions with various biological targets, making it a promising candidate for drug development.

Recent research has focused on elucidating the pharmacokinetic and pharmacodynamic properties of N-(3-aminophenyl)hexanamide. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that this compound exhibits favorable bioavailability and metabolic stability in preclinical models. The study utilized advanced analytical techniques, including liquid chromatography-mass spectrometry (LC-MS), to quantify the compound's distribution and elimination profiles. These findings are critical for understanding the compound's potential as a therapeutic agent.

Another key area of investigation has been the compound's mechanism of action. Preliminary data from in vitro assays suggest that N-(3-aminophenyl)hexanamide may modulate specific signaling pathways involved in inflammation and cell proliferation. For instance, a 2024 study in Biochemical Pharmacology reported that the compound inhibits the activity of certain kinases, which are often implicated in cancer and autoimmune diseases. This inhibitory effect was observed at nanomolar concentrations, highlighting the compound's potency.

In addition to its therapeutic potential, N-(3-aminophenyl)hexanamide has also been explored for its role in chemical biology. Researchers have synthesized derivatives of this compound to investigate structure-activity relationships (SAR). A recent paper in ACS Chemical Biology (2024) detailed the synthesis and evaluation of several analogs, identifying key structural features that enhance binding affinity to target proteins. These insights are invaluable for the design of next-generation therapeutics.

Despite these promising findings, challenges remain in the development of N-(3-aminophenyl)hexanamide as a drug candidate. Issues such as off-target effects and formulation stability need to be addressed in future studies. However, the compound's unique properties and the growing body of research supporting its potential make it a compelling subject for further investigation. Ongoing studies are expected to provide deeper insights into its applications and limitations.

In conclusion, N-(3-aminophenyl)hexanamide (CAS: 231954-22-6) represents a promising avenue for research in chemical biology and drug development. Its favorable pharmacokinetic profile, potent biological activity, and potential for structural optimization position it as a valuable compound for future therapeutic applications. Continued research will be essential to fully realize its potential and overcome existing challenges.

• 22987-10-6(N-(3-aminophenyl)propanamide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)